search
Back to results

A Trial to Demonstrate Bioequivalence Between Two Insulin Degludec/Liraglutide Formulations, B5 and V2 in Healthy Subjects

Primary Purpose

Diabetes, Diabetes Mellitus, Type 2, Healthy

Status
Completed
Phase
Phase 1
Locations
Germany
Study Type
Interventional
Intervention
insulin degludec/liraglutide
insulin degludec/liraglutide
Sponsored by
Novo Nordisk A/S
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Diabetes

Eligibility Criteria

18 Years - 55 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Healthy male and female volunteers
  • Body mass index (BMI) between 18.5 and 27.0 kg/m^2 (both inclusive)
  • Body weight between 60 and 90 kg (both inclusive)

Exclusion Criteria:

  • Female of child-bearing potential who is pregnant, breast-feeding or intend to become pregnant or is not using adequate contraceptive methods. Adequate contraceptive measures are implants, injectables, combined oral contraceptives, hormonal intrauterine device, sexual abstinence or vasectomised partner
  • History or presence of cancer, or any clinically significant cardiovascular, respiratory, metabolic, renal, hepatic, gastrointestinal, endocrine (incl. diabetes), haematological, dermatological, venereal, neurological, psychiatric diseases or other major disorders
  • Use of any prescription or non-prescription medication, except for paracetamol, acetylsalicylic acid, contraceptives and vitamins (but including mega-dose vitamin therapy, as judged by the investigator) within 2 weeks before the trial
  • Drug or alcohol abuse

Sites / Locations

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

Insulin degludec/liraglutide, B5

Insulin degludec/liraglutide, V2

Arm Description

Subjects will be randomly allocated to the two single dose administrations (one for each of the two IDegLira formulations) on the two separate dosing visits. The two administration days will be separated by a wash-out period of 7-15 days.

Subjects will be randomly allocated to the two single dose administrations (one for each of the two IDegLira formulations) on the two separate dosing visits. The two administration days will be separated by a wash-out period of 7-15 days.

Outcomes

Primary Outcome Measures

Area under the serum IDeg concentration time curve after single dose
Maximum observed serum IDeg concentration after single dose
Area under the plasma liraglutide concentration time curve after single dose
Maximum observed plasma liraglutide concentration after single dose

Secondary Outcome Measures

Area under the serum IDeg concentration time curve after single dose
Time to maximum IDeg concentration
Terminal elimination half-life for IDeg after single dose
Area under the plasma liraglutide concentration time curve after single dose
Time to maximum plasma liraglutide concentration after single dose
Terminal elimination half-life of liraglutide after single dose

Full Information

First Posted
August 2, 2013
Last Updated
November 7, 2013
Sponsor
Novo Nordisk A/S
search

1. Study Identification

Unique Protocol Identification Number
NCT01916174
Brief Title
A Trial to Demonstrate Bioequivalence Between Two Insulin Degludec/Liraglutide Formulations, B5 and V2 in Healthy Subjects
Official Title
A Trial to Demonstrate Bioequivalence Between Two Insulin Degludec/Liraglutide Formulations, B5 and V2 in Healthy Subjects
Study Type
Interventional

2. Study Status

Record Verification Date
November 2013
Overall Recruitment Status
Completed
Study Start Date
August 2013 (undefined)
Primary Completion Date
November 2013 (Actual)
Study Completion Date
November 2013 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Novo Nordisk A/S

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
This trial is conducted in Europe. The aim of this trial is to assess the expected biological equivalence between two formulations of insulin degludec/liraglutide (IDegLira) with identical active ingredient in healthy volunteers.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes, Diabetes Mellitus, Type 2, Healthy

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Crossover Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
50 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Insulin degludec/liraglutide, B5
Arm Type
Experimental
Arm Description
Subjects will be randomly allocated to the two single dose administrations (one for each of the two IDegLira formulations) on the two separate dosing visits. The two administration days will be separated by a wash-out period of 7-15 days.
Arm Title
Insulin degludec/liraglutide, V2
Arm Type
Experimental
Arm Description
Subjects will be randomly allocated to the two single dose administrations (one for each of the two IDegLira formulations) on the two separate dosing visits. The two administration days will be separated by a wash-out period of 7-15 days.
Intervention Type
Drug
Intervention Name(s)
insulin degludec/liraglutide
Intervention Description
Subject will receive a single injection (s.c.) of IDegLira B5
Intervention Type
Drug
Intervention Name(s)
insulin degludec/liraglutide
Intervention Description
Subject will receive a single injection (s.c.) of IDegLira V2
Primary Outcome Measure Information:
Title
Area under the serum IDeg concentration time curve after single dose
Time Frame
Assessed from 0 to 120 hours
Title
Maximum observed serum IDeg concentration after single dose
Time Frame
Assessed from 0-120 hours
Title
Area under the plasma liraglutide concentration time curve after single dose
Time Frame
Assessed from 0-72 hours
Title
Maximum observed plasma liraglutide concentration after single dose
Time Frame
Assessed from 0-72 hours
Secondary Outcome Measure Information:
Title
Area under the serum IDeg concentration time curve after single dose
Time Frame
Assessed from 0-120 hours
Title
Time to maximum IDeg concentration
Time Frame
Assessed from 0-120 hours
Title
Terminal elimination half-life for IDeg after single dose
Time Frame
Assessed from 0-120 hours
Title
Area under the plasma liraglutide concentration time curve after single dose
Time Frame
Assessed from 0-72 hours
Title
Time to maximum plasma liraglutide concentration after single dose
Time Frame
Assessed from 0-72 hours
Title
Terminal elimination half-life of liraglutide after single dose
Time Frame
Assessed from 0-72 hours

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
55 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Healthy male and female volunteers Body mass index (BMI) between 18.5 and 27.0 kg/m^2 (both inclusive) Body weight between 60 and 90 kg (both inclusive) Exclusion Criteria: Female of child-bearing potential who is pregnant, breast-feeding or intend to become pregnant or is not using adequate contraceptive methods. Adequate contraceptive measures are implants, injectables, combined oral contraceptives, hormonal intrauterine device, sexual abstinence or vasectomised partner History or presence of cancer, or any clinically significant cardiovascular, respiratory, metabolic, renal, hepatic, gastrointestinal, endocrine (incl. diabetes), haematological, dermatological, venereal, neurological, psychiatric diseases or other major disorders Use of any prescription or non-prescription medication, except for paracetamol, acetylsalicylic acid, contraceptives and vitamins (but including mega-dose vitamin therapy, as judged by the investigator) within 2 weeks before the trial Drug or alcohol abuse
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Global Clinical Registry (GCR, 1452)
Organizational Affiliation
Novo Nordisk A/S
Official's Role
Study Director
Facility Information:
City
Neuss
ZIP/Postal Code
41460
Country
Germany

12. IPD Sharing Statement

Links:
URL
http://novonordisk-trials.com
Description
Clinical Trials at Novo Nordisk

Learn more about this trial

A Trial to Demonstrate Bioequivalence Between Two Insulin Degludec/Liraglutide Formulations, B5 and V2 in Healthy Subjects

We'll reach out to this number within 24 hrs